Envafolimab
- Generic Name
- Envafolimab
- Drug Type
- Biotech
- CAS Number
- 2102192-68-5
- Unique Ingredient Identifier
- ES1M06M6QH
- Indication
用于不可切除或转移性微卫星高度不稳定（MSI-H）或错配修复基因缺陷型（dMMR）的成人晚期实体瘤患者的治疗，包括既往经过氟尿嘧啶类、奥沙利铂和伊立替康治疗后出现疾病进展的晚期结直肠癌患者以及既往治疗后出现疾病进展且无满意替代治疗方案的其他晚期实体瘤患者。
A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients
- First Posted Date
- 2020-07-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 207
- Registration Number
- NCT04465890
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, China
KN035 in Patients With Advanced Multiple Primary Tumors
- First Posted Date
- 2019-12-02
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04182789
- Locations
- 🇨🇳
RenJi Hospital, Shanghai, Shanghai, China
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2017-08-14
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 35
- Registration Number
- NCT03248843
- Locations
- 🇯🇵
St. Marianna University School of Medicine Hospital, Kawasaki, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
- First Posted Date
- 2017-04-05
- Last Posted Date
- 2022-03-03
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 287
- Registration Number
- NCT03101488
- Locations
- 🇨🇳
Zhongshan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
🇨🇳First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2016-07-11
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT02827968
- Locations
- 🇺🇸
Horizon Oncology Research, INC, Lafayette, Indiana, United States
🇺🇸South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.